FDA Approval Deal History & Licensing Activity
FDA Approval is a life sciences. Over the past three years, FDA Approval has been involved in 12 licensing and acquisition transactions, with a primary focus on Small Molecules (12 deals).
Deals (12mo)
11
Active Trials
0
Top Modality
Small Molecules
Focus Area
Other
FDA Approval Recent Deal Activity
Licensing, acquisition, and partnership transactions involving FDA Approval in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| DAPAGLIFLOZIN | Lupin | Small Molecules | Approved | other | Apr 2026 |
| NINTEDANIB | Cipla | Small Molecules | Approved | other | Apr 2026 |
| FOUNDAYO | Eli Lilly | Small Molecules | Approved | other | Apr 2026 |
FDA Approval Pipeline Focus
Therapeutic areas and modalities where FDA Approval is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches FDA Approval's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About FDA Approval Licensing & Deal Activity
FDA Approval is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 12 deals over the past three years, FDA Approval ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for FDA Approval include Other (16 deals and trials), and Respiratory (1 deal and trial). In terms of modality, FDA Approval has shown particular interest in small molecules, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for FDA Approval and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against FDA Approval's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.